Japan

In Japan, the regulation of health products including pharmaceuticals, medical devices, diagnostics, and digital health solutions is governed by the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Pharmaceutical and Medical Device Act, PMD Act), which came into force in 2014 as a major revision of the former Pharmaceutical Affairs Law. The primary regulatory authority is the Pharmaceuticals and Medical Devices Agency (PMDA), which conducts scientific reviews, post-market safety surveillance, and relief services for adverse health effects. Market approval (marketing authorization, known as 'Shonin') is ultimately granted by the Ministry of Health, Labour and Welfare (MHLW), based on PMDA's review outcomes. The review timeline typically ranges from 12 to 24 months depending on product classification, priority review designation, and the complexity of the submission, though expedited pathways such as Sakigake Designation and Priority Review can significantly reduce this window for innovative products.

A foreign manufacturer seeking to place health products on the Japanese market must appoint a Marketing Authorization Holder (MAH), which is a Japan-based legal entity responsible for the product throughout its lifecycle, including post-market vigilance and communication with PMDA and MHLW. Japan accepts the Common Technical Document (CTD) format for dossier submissions, aligned with ICH guidelines, and participates actively in ICH harmonization efforts. Clinical data requirements have historically necessitated Japan-specific or Asia-Pacific clinical trial data; however, recent reforms under the Sakigake strategy and revisions to the PMD Act now allow greater acceptance of global clinical data, provided Japanese patient representation or bridging data can be demonstrated. Digital health products, including Software as a Medical Device (SaMD), are regulated under a distinct framework introduced in 2014 and further refined in subsequent MHLW guidance, with classification tiers determining the level of review required. Efforts to streamline early consultation programs (PMDA's advance consultation system) and the introduction of conditional early approval pathways reflect Japan's ongoing commitment to reducing regulatory lag while maintaining rigorous safety and efficacy standards.

Japan's public healthcare procurement operates within a highly structured, nationally coordinated framework. The Ministry of Health, Labour and Welfare (MHLW) holds overarching policy authority, while the National Health Insurance (NHI) system serves as the primary payer for pharmaceutical and medical device expenditures at the national level. Drug and device pricing is determined through the NHI Price Listing (Yakka Kijun) and the NHI Medical Device Coverage List, with MHLW revising listed prices on a biennial basis (moving toward annual revisions for pharmaceuticals since 2018). Hospitals and healthcare institutions, many of which are public or quasi-public, procure health products through tenders and purchasing agreements that must comply with NHI reimbursement pricing. Regional and prefecture-level authorities play a role in operational procurement for public hospitals and public health programs, but national pricing and coverage decisions are centralized, making the MHLW-NHI framework the decisive gateway for broad market access.

The private healthcare sector in Japan is substantial, encompassing private hospitals, clinics, and pharmacy chains that procure directly from wholesalers and distributors operating within the NHI pricing framework. Unlike many lower- and middle-income markets, Japan does not rely meaningfully on international donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income country with a comprehensive public insurance system. However, Japan is an active donor to global health initiatives and its manufacturers participate in international procurement programs. Local manufacturing preference policies are not formally codified as explicit procurement preferences in the way seen in some other markets; however, Japan maintains strategic domestic manufacturing capacity for pharmaceuticals, vaccines, and medical devices, and government industrial policy through the Ministry of Economy, Trade and Industry (METI) actively supports strengthening domestic supply chains, a priority that was reinforced by supply resilience concerns arising from the COVID-19 pandemic.